briefpedia.org
Articles/García's Academic Journey in Biotechnology and Cancer Research
Garcíabiotechnologycancer researchtranslational medicineantibody-drug conjugates

García's Academic Journey in Biotechnology and Cancer Research

García's Academic Journey in Biotechnology and Cancer Research

The pursuit of breakthroughs in oncology requires a rigorous foundation in biological sciences and a commitment to translational medicine—the process of turning laboratory discoveries into clinical treatments. The academic and professional trajectory of García exemplifies this path, moving from foundational biotechnology studies to cutting-edge drug discovery for some of the most challenging forms of cancer.

Educational Foundation

García began her academic career at the University of León, where she developed her expertise in the intersection of biology and technology. She earned a bachelor's degree in biotechnology in 2012, followed by a master's degree in biomedical and biological research in 2013.

Doctoral Research and Specialization

Transitioning to the University of Salamanca, García focused her efforts on the nuclear biology of cancer. Serving as a university research assistant for the Spanish National Research Council, she conducted critical research on cancer medicine. Under the guidance of Atanasio Pandiella Alonso at the university's Cancer Research Centre, she earned her doctorate cum laude in 2018.

Her doctoral dissertation investigated the mechanisms of resistance to antibody-drug conjugates (targeted therapies that combine an antibody with a potent drug) specifically within ErbB receptors. This work was highly recognized, earning her the university's Outstanding Doctorate Award in 2019.

Postdoctoral Work and Drug Discovery

Since 2019, García has advanced her career as a postdoctoral researcher at the Spanish National Cancer Research Centre. Working within the laboratory of Mariano Barbacid, she has specialized in experimental oncology and drug discovery.

Her current research focuses on identifying therapeutic targets to combat specific cancers, particularly lung and pancreatic cancer. A primary area of her investigation involves RAF1 selective degraders, which are molecules designed to remove specific proteins that drive cancer growth.

Beyond the laboratory, García has expanded her professional skill set through a six-month training programme at the IE Business School in Madrid in 2021. She has also dedicated her time to philanthropy as a volunteer for the Spanish Association Against Cancer, a nonprofit organization.

Key Facts

  • Highest Degree: Doctorate cum laude in nuclear biology of cancer and translational medicine (2018).
  • Major Award: Outstanding Doctorate Award from the University of Salamanca (2019).
  • Research Focus: Drug discovery for lung and pancreatic cancer, specifically RAF1 selective degraders.
  • Specialization: Resistance mechanisms of antibody-drug conjugates in ErbB receptors.
  • Institutional Affiliations: University of León, University of Salamanca, and the Spanish National Cancer Research Centre.
Academic and Professional Timeline of García
Year Milestone/Institution Focus/Achievement
2012 University of León Bachelor's in Biotechnology
2013 University of León Master's in Biomedical and Biological Research
2018 University of Salamanca Doctorate cum laude in Nuclear Biology of Cancer
2019 University of Salamanca Outstanding Doctorate Award
2019–Present Spanish National Cancer Research Centre Postdoctoral Research in Experimental Oncology
2021 IE Business School 6-month training programme

Frequently Asked Questions

What was the focus of García's doctoral dissertation?

Her dissertation focused on the mechanisms of resistance to antibody-drug conjugates in ErbB receptors.

Which types of cancer is García currently researching?

She is leading projects to discover drugs specifically for lung cancer and pancreatic cancer.

What are RAF1 selective degraders?

They are a therapeutic target used in García's research to combat certain forms of cancer by degrading specific proteins.

Where did García complete her early university education?

She earned both her bachelor's degree in biotechnology and her master's degree in biomedical and biological research from the University of León.

Has García been involved in any nonprofit work?

Yes, she has volunteered for the Spanish Association Against Cancer, which is a nonprofit organization.

References

  1. The title of her doctoral dissertation, in Spanish, is: "Anticuerpos conjugados a fármacos frente a receptores ErbB: Nuevas indicaciones y mecanismos de resistencia".[4]
  2. "Sara García Alonso". esa.int. Archived from the original on 31 December 2022. Retrieved 31 December 2022.
  3. Corbella, Josep (23 November 2022). "Sara García Alonso, la investigadora del cáncer seleccionada como astronauta" [Sara García Alonso, the cancer researcher selected as an astronaut]. La Vanguardia (in Spanish). Retrieved 23 November 2022.
  4. Rey, Álvaro Sánchez (23 November 2022). "Artes marciales y feminismo: así es Sara García, la nueva astronauta española de la ESA" [Martial arts and feminism: this is Sara García, the new Spanish astronaut at ESA]. Vanitatis (in Spanish). El Confidencial. Retrieved 23 November 2022.
  5. "Tesis Defendidas en la Universidad de Salamanca en el Curso 2019/20" [Theses Defended at the University of Salamanca in the 2019/20 Academic Year] (PDF) (in Spanish). University of Salamanca. Retrieved 31 December 2022.

Continue reading

Related articles

García's Professional Football Journey: From San Agustín to Deportivo de La CoruñaGenome Sequencing: Mapping the Blueprint of LifeMicrobiology: The Science of the Invisible WorldDNA Sequencing: Technologies, History, and Modern Applications